Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $13.9 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas.
Shares of this leading research and diagnostic firm have outperformed the broader market over the past year. RVTY has gained 39.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.5%. In 2026, RVTY’s stock rose 28.9%, surpassing the SPX’s 12.1% rise on a YTD basis.
